Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2003-06-30

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if Divalproex Sodium can be used to Treat and Prevent Depression in Patients with Bipolar Disorder who have Comorbid Alcohol Dependence/Abuse.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Depakote ER Therapy for Mania Comorbid With Substance Abuse

NCT00208195

Bipolar Disorder Mania Substance Abuse +1 more

COMPLETED PHASE4

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

NCT00060905

Bipolar Disorder

COMPLETED PHASE3

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

NCT00202514

Alcoholism Alcohol Related Disorders Mood Disorders

COMPLETED PHASE2/PHASE3

Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER

NCT00211250

Mood Disorder

COMPLETED PHASE4

Depakote ER in Bipolar Depression

NCT00186186

Depression, Bipolar

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Over half of all patients with bipolar disorder have comorbid substance abuse. The most common substance of abuse is alcohol, which is most commonly associated with the depressed phase of the illness. Although there are available treatments for bipolar depression, no studies have been done to evaluate efficacy in bipolar patients with comorbid substance abuse disorders. Given the independent open-label evidence for efficacy and safety of divalproex sodium in alcohol abuse and bipolar depression, divalproex sodium is the most likely candidate for potential success in bipolar depressed patients with comorbid alcohol abuse or dependence. The purpose of this study is to determine if Divalproex Sodium can be used to Treat and Prevent Depression in Patients with Bipolar Disorder who have Comorbid Alcohol Dependence/Abuse.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar I or II Depression and Alcohol Abuse or Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Depakote ER

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MADRS \>= 20 at screen and 18 at baseline
* YMRS =\< 11 at screen and baseline
* DMS-IV criteria for past manic or hypomanic episode based on the SCID
* DSM-VI criteria for alcohol dependence or abuse based on the SCID.
* Alcohol dependence/abuse confirmed by corroboration from family member
* Negative urine pregnancy test

Exclusion Criteria

* Inability to give informed consent
* Inability to give reliable assessment of alcohol consumption
* Evidence of alcohol consumption one week prior to baseline
* Liver function tests greater than 3X upper limit of normal at screen
* History of active hepatitis or hepatic encephalopathy
* History of pancreatitis
* History of adverse reaction to divalproex sodium
* History of seizure other than directly associated w/prior alcohol withdrawl
* History of major head trauma with LOC \> 10 min. or skull fracture
* Hisotry of hypertension or neurologic illness
* If female, not practicing an effective form of birth control

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No